Pharmaceutical Technology1d
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
clinicaltrialsarena2d
Microbion reports topline data from Phase II study of DFI therapy
Microbion has reported positive topline results from its Phase II study of pravibismane, a topical treatment for DFI.
clinicaltrialsarena3d
Longboard commences Phase III trial of bexicaserin for DEEs seizure treatment
Longboard has commenced the Phase III DEEp OCEAN Study of bexicaserin for treating seizures linked to DEEs in two years and ...
Pharmaceutical Technology4d
Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo
Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...